| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0169-5002(99)00045-8 |
| P698 | PubMed publication ID | 10574676 |
| P50 | author | Carlos Camps | Q37831591 |
| Jordi Roig | Q67503559 | ||
| P2093 | author name string | R Rosell | |
| A Abad | |||
| J Padilla | |||
| J Maestre | |||
| A Cantó | |||
| J Gómez-Codina | |||
| J Javier Sánchez | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| lung cancer | Q47912 | ||
| randomized controlled trial | Q1436668 | ||
| P304 | page(s) | 7-14 | |
| P577 | publication date | 1999-10-01 | |
| P1433 | published in | Lung Cancer | Q641464 |
| P1476 | title | Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial | |
| P478 | volume | 26 |
| Q27002509 | 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer |
| Q39754886 | A phase II study of weekly paclitaxel, cisplatin and concurrent radiation therapy for locally-advanced unresectable non-small cell lung cancer: early closure due to lack of efficacy |
| Q73955120 | A preoperative alternating chemotherapy and radiotherapy program for patients with stage IIIA (N2) non-small cell lung cancer |
| Q36780623 | A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. |
| Q40584517 | Accelerated hyperfractionated radiation, concurrent paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancer |
| Q36296453 | Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer |
| Q44037869 | Adenoviral herpes simplex virus thymidine kinase gene therapy in an orthotopic lung cancer model |
| Q36430299 | Adjuvant and neoadjuvant chemotherapy in NSCLC: a paradigm shift |
| Q35076202 | Adjuvant therapy for resected non-small cell lung cancer |
| Q43880102 | An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer |
| Q21558544 | Analysis of research output parameters: density equalizing mapping and citation trend analysis |
| Q46378860 | Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). |
| Q34569389 | Building a better therapy for stage IIIA non-small cell lung cancer |
| Q33348693 | Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958). |
| Q24244191 | Chemotherapy and surgery versus surgery alone in non-small cell lung cancer |
| Q34461773 | Chemotherapy for early stage non-small cell lung cancer. |
| Q35200383 | Chemotherapy of lung cancer: A global perspective of the role of ifosfamide |
| Q41842837 | Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer |
| Q36785118 | Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung |
| Q35627621 | Combined modality treatment of non-small-cell lung cancer |
| Q74079755 | Comment on Rosell et al., Roth et al. and Gandara et al., Lung Cancer |
| Q36545344 | Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy |
| Q38263799 | Current status of induction treatment for N2-Stage III non-small cell lung cancer |
| Q34384459 | Development of treatment strategies in locally advanced non-small cell lung cancer (take home messages). |
| Q34951761 | Diagnosis and management of early lung cancer |
| Q35039285 | Does pneumonectomy have a role in the treatment of stage IIIA non-small cell lung cancer? |
| Q59274190 | Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q36247875 | Evolution of induction chemotherapy for non-small cell lung cancer over the last 30 years: A surgical appraisal |
| Q35782899 | Gemcitabine (Gemzar) in non-small cell lung cancer |
| Q43594786 | High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study |
| Q53638389 | Histologic Assessment of Non–Small Cell Lung Carcinoma after Neoadjuvant Therapy |
| Q36302496 | Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy |
| Q46743460 | How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study |
| Q37478345 | Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non-Small Cell Lung Cancer |
| Q35543230 | Induction chemotherapy followed by radical local therapy for locally advanced non‐small cell lung cancer |
| Q35142833 | Induction chemotherapy in early-stage non-small-cell lung cancer |
| Q34107782 | Induction chemotherapy or chemoradiotherapy before surgery for non-small-cell lung cancer |
| Q34462571 | Induction chemotherapy with gemcitabine and cisplatin in stage III non-small cell lung cancer |
| Q35621593 | Induction treatment before surgery for non-small cell lung cancer |
| Q35537379 | Levels of evidence and grades of recommendations in general thoracic surgery. |
| Q64990196 | Local control of locally advanced (N2) non-small cell lung cancer: when and how? |
| Q61448599 | Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome |
| Q58605252 | Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: a propensity-matched analysis |
| Q35923256 | Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis |
| Q94093273 | Lung cancer |
| Q34982142 | Lung cancer--where are we today? Current advances in staging and nonsurgical treatment. |
| Q33372250 | Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease). |
| Q35008704 | Neoadjuvant and adjuvant therapy of non-small cell lung cancer |
| Q73342944 | Neoadjuvant chemoradiotherapy of stage III non-small-cell lung cancer |
| Q47137416 | Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials |
| Q44227098 | Neoadjuvant chemotherapy with gemcitabine and cisplatin in stage IIIA/B non-small cell lung cancer |
| Q34447477 | Neoadjuvant strategies for non-small cell lung cancer. |
| Q34733944 | New strategies in the treatment of resectable non-small cell lung cancer |
| Q44874525 | Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection. |
| Q36195470 | Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the Prognosis |
| Q37208623 | Perioperative outcomes and lymph node assessment after induction therapy in patients with clinical N1 or N2 non-small cell lung cancer |
| Q43061648 | Perspectives in adjuvant chemotherapy in NSCLC. |
| Q57569751 | Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients |
| Q73483272 | Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery |
| Q92314142 | Preoperative Risk Assessment of Lymph Node Metastasis in cT1 Lung Cancer: A Retrospective Study from Eastern China |
| Q36838177 | Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review |
| Q37323898 | Preoperative concurrent radiochemotherapy and surgery for stage IIIA non-small cell lung cancer |
| Q36644057 | Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer |
| Q90603658 | Preoperative radiation may improve the outcomes of resectable IIIA/N2 non-small-cell lung cancer patients: A propensity score matching-based analysis from surveillance, epidemiology, and end results database |
| Q40684247 | Preoperative treatment strategies in stage III non-small cell lung cancer |
| Q77225043 | Principles of induction chemotherapy for non-small cell lung cancer |
| Q36614079 | Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study |
| Q33568631 | Prognostic factors and long term results of neo adjuvant therapy followed by surgery in stage IIIA N2 non-small cell lung cancer patients |
| Q40640597 | Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer |
| Q53125167 | Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy. |
| Q40521275 | Quality of life issues in non-small cell lung cancer |
| Q46330671 | Results of surgical treatment after neoadjuvant chemotherapy for stage III non-small cell lung cancer. |
| Q44630217 | Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer |
| Q33829263 | Role of multimodality treatment for lung cancer. |
| Q40406773 | Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages |
| Q35543216 | Surgery for locally advanced non‐small cell lung cancer |
| Q77225027 | Surgery for non-small cell lung cancer |
| Q33813436 | Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial |
| Q53288192 | Survival of patients with clinical stage IIIA non–small cell lung cancer after induction therapy: Age, mediastinal downstaging, and extent of pulmonary resection as independent predictors |
| Q88186501 | Survivin mRNA Level in Blood Predict the Efficacy of Neoadjuvant Chemotherapy in Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer |
| Q33886353 | The Role of Neoadjuvant Trials in Drug Development for Solid Tumors |
| Q39572054 | The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis |
| Q35544772 | The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer |
| Q33613087 | The long-term prognosis of induction chemotherapy followed by surgery for N2 non-small cell lung cancer: A retrospective case series study |
| Q34461776 | The role of chemotherapy in early non-small-cell lung cancer management. |
| Q33877447 | The role of induction therapy in the management of resectable non-small cell lung cancer |
| Q37642455 | Therapeutic management options for stage III non-small cell lung cancer |
| Q36158717 | Therapeutic targeting of receptor tyrosine kinases in lung cancer |
| Q39034554 | Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials |
| Q74513402 | Treatment and survival of patients with non-small cell lung cancer Stage IIIA diagnosed in 1989-1994: a study in the region of the Comprehensive Cancer Centre East, The Netherlands |
| Q35551162 | Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents |
| Q36852163 | Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer |
| Q37085999 | What is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941? |
| Q81205224 | [Surgical treatment of non-small cell lung cancer] |
Search more.